One of the spearheads of NVI's policy is to contribute to the
availability of vaccine world-wide. The NVI is willing to offer his
facilities and knowledge to provide other institutes in middle- and
lower income countries, the possibility to build, improve and/or
expand their own production facility. NVI realizes this by
technology transfer to competent vaccine producers in lower- and
middle income countries. For example, NVI has recently developed a
production process for Hib conjugate vaccine that has been
successfully transferred to vaccine producers in India and
Indonesia.
Also, the NVI works together in vaccine development projects with
governmental institutions with vaccine development capabilities in
Europe. Such as the Staten Serum Institute (Denmark), The Health
Protection Agency (UK), KTL (Finland), NCE (Hungary) and
Cantacuzino Imstitute (Romania).
And last but certainly not least, the NVI functions as training
centre within the WHO Global Training Network for Vaccine Quality
(GTN-VQ) and the WHO Initiative for Vaccine Research (IVR).
WHO, influenza and polio...
Under a Memorandum of Understanding between WHO and NVI, signed for
an initial five-year period, NVI is establishing since early 2008
in-house an egg-based pilot seasonal influenza vaccine production
process suitable for up scaling, training and technology transfer
to manufacturers in lower- and middle income countries. This
project is called the International Technology Platform for
Influenza Vaccines (ITPIV). Read more here
or use this
link to navigate to the website.
Another WHO-project is Sabin-IPV. In this project, The NVI will
establish, test and document a production process for
Sabin-inactivated polio vaccine (IPV) based on the current Salk-IPV
production technology. Read more
here or use this link to the website.